This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Ecole Des Hautes Etudes En Sante Publique (Ehesp), National Institute of Health and Medical Research, Université De Rennes 1. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2026
Title: The Innovations of Georges Baffet
Introduction
Georges Baffet is a notable inventor based in Le Rheu, France. He has made significant contributions to the field of medical research, particularly in the area of human hepatic progenitors. His work has implications for advancements in liver-related therapies and treatments.
Latest Patents
Georges Baffet holds a patent for a "Method of Culturing Immortalized Human Hepatic Progenitors or Cells." This innovative method is crucial for the development of liver cells that can be used in various medical applications. His patent portfolio includes 1 patent that showcases his expertise in this specialized field.
Career Highlights
Throughout his career, Baffet has worked with esteemed institutions such as the National Institute of Health and Medical Research and Université De Rennes 1. His experience in these organizations has allowed him to collaborate with leading experts in the field of medical research.
Collaborations
Georges Baffet has collaborated with notable colleagues, including Marie Cuvellier and Frédéric Ezan. These partnerships have contributed to the advancement of research in hepatic progenitor cells and their applications in medicine.
Conclusion
Georges Baffet's contributions to the field of medical research through his innovative patent and collaborations highlight his importance as an inventor. His work continues to influence advancements in liver therapies and medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile